Clinical Trial

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-22; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Recruiting 2024-07-26
Trial Details
NCT Number NCT06431490
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Biliary Tract Cancer
Enrollment 102 participants
Start Date 2024-07-22
Primary Completion 2027-05 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08